Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab +/- Linrodostat or Ipilimumab in Melanoma
NCT04007588Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of linrodostat in melanoma (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Major Pathologic Response Rate at 2 years. Planned start Sep 2019; status: withdrawn.
02
Drugs
linrodostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04007588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007588.